

## Clinical Oncology

### Group leader

Barnadas Molins, Agustí (FGS)

### Researchers

Andrés Granyo, Marta (FGS)  
 Anguera Palacios, Geòrgia (FGS)  
 Arqueros Núñez, Cristina (FGS)  
 Barba Joaquín, Andrés (FGS)  
 Calvo Verges, Núria (FGS)  
 Cerdà Serdà, Paula (FGS)  
 Cotaina Recio, Maria (FGS)  
 Escuin Borràs, Daniel (IR)  
 Gallego Rubio, Óscar Salvador (FGS)  
 Juan Linares, Eva (FGS)  
 Larrañaga Blanc, Itziar (FGS)  
 López Pousa, Antonio (FGS)  
 López SanMartín, Consuelo (FGS)  
 Majem Tarruella, Margarita (FGS)  
 Maroto Rey, José Pablo (FGS)  
 Mora Brugués, Josefina (FGS)  
 Páez López-Bravo, David (FGS)  
 Ramón y Cajal Asensio, Teresa (FGS)  
 Romero Montenegro, Daniel (FGS)  
 Salazar Blanco, Juliana (IR)  
 Sebio García, Ana (FGS)  
 Serra López, Jorgina (FGS)  
 Terés Lleida, Raúl (FGS)  
 Tibau Martorell, Ariadna (FGS)  
 Virgili Manrique, Anna Cristina (FGS)

### Research technicians

Alfonso Ruiz, Rosa (IR)  
 Andrés Nieto, Marta (IR)  
 Bell Ramírez, Olga Lúdia (IR)  
 Benítez Manzananas, Laia (IR)  
 Calero Pérez, María del Pilar (IR)  
 Carmona Alonso, Ana (IR)  
 Castells Tello, Diana (IR)  
 Clua Serra, Marina (IR)  
 Colomer Merino, Lucía (IR)  
 Cruz Ibáñez, Cristina (IR)  
 García Belinchón, Mercé (IR)  
 Gisbert Beamud, Alexandra (IR)  
 González Guerrero, Laura (IR)  
 Hernández García, Ricardo (IR)  
 Lavernia Rosell, Laia (IR)  
 Layana Antepara, Michelle Elizabeth (IR)  
 Llobet Busquets, Mireia (IR)  
 Martínez Aranda, Rodrigo Antonio (IR)  
 Menéndez Cuervo, Dulce María (IR)  
 Molina Bayona, Sílvia (IR)  
 Moreno Gómez, Laura (IR)  
 Pérez Gorrini, Tiziana Giselle (IR)  
 Ramírez García, Ona (IR)  
 Reyes Vilasalo, Judith (IR)  
 Ribas Bellavista, Laia (IR)  
 Ribas Carbonell, Romina (IR)  
 Roca Solà, Marc (IR)  
 Sallés Niubó, Mireia (IR)  
 Suris Cumicheo, Paola Maria (IR)  
 Tortosa Gallego, Belén (IR)  
 Tricas Albareda, Andrea (IR)  
 Vall Montero, Gaudi (IR)  
 Van Veen Romero, Erika (IR)



### DESCRIPTION

Our research group conduct clinical trials to assess new therapeutic strategies, the effectiveness of targeted treatments and detection of residual disease, and research studies to evaluate prognostic and predictive molecular biomarkers, the molecular mechanisms of action and resistance to drugs and the pharmacogenetics of cancer. We aim to translate this knowledge to predict patients at higher risk of recurrence, select those more likely to benefit from specific therapies, and assess the risk of treatment toxicity according to patients' genetic characteristics.

### MAIN LINES OF RESEARCH

- Breast cancer. (Barnadas Molins, Agustí; Tibau Martorell, Ariadna; Arqueros Núñez, Cristina; Andrés Granyo, Marta; Escuin Borràs, Daniel; Dr. Rivera).
- Lung cancer and melanoma. (Majem Tarruella, Margarita; Barba Joaquín, Andrés).
- Neuroendocrine tumors. (Páez López-Bravo, David).
- Head and neck and Central neural tumors. (Gallego Rubio, Oscar Salvador; López Pousa, Antonio).
- Hereditary cancer and genetic counselling. (Ramón Y Cajal Asensio, Teresa; Calvo Verges, Nuria; López SanMartín, Consuelo).
- Digestive tumors. (Páez López-Bravo, David; Sebio García, Ana; Virgili Manrique, Anna Cristina; Cerdà Serdà, Paula).
- Urological tumors. (Maroto Rey, José Pablo; Anguera Palacios, Georgia).

- Sarcoma unit. (López Pousa, Antonio; Sebio García, Ana; Terés Lleida, Raul; Sebio García, Ana).
- Laboratory of translational research. (Escuin Borràs, Daniel; Salazar Blanco, Juliana).

## SCIENTIFIC CHALLENGES

- To increase our participation in stable cooperative research groups in cancer (CIBER; RETICS, etc).
- To improve our success rate in national and international competitive grant calls and postdoctoral and clinical research fellowships.
- To promote translational research in cancer in cooperation with other internal and external research groups.
- To develop new drugs in phase 0/1 studies.

## ACTIVE & AWARDED GRANTS

- Barnadas Molins, Agustí. Recerca Clínica en Oncologia. 2021 SGR 00827. Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR). Duration: 2022-2025. 40.000 €.
- Páez López-Bravo, David. Integración de la farmacogenética y la telemedicina mediante salud móvil para el manejo de los efectos adversos en pacientes con cáncer colorrectal (ePGx study). PI21/01913. Instituto de Salud Carlos III (ISCIII). Duration: 2022-2026. 63.525,00 €
- Tibau Martorell, Ariadna. Beneficio clínico, precio y acceso de los nuevos medicamentos contra el cancer en España y en el resto de Europa: un análisis internacional. PI23/00742. Instituto de Salud Carlos III. Duration: 2024-2026. 37.500 €.

## SCIENTIFIC PRODUCTION

- Abu A, Krayim B, Amir E, Tibau A, Robson ME, Abuhadra N, Chen Y, Shepshelovich D, Goldvaser H. The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review. CRITICAL REVIEWS IN ONCOLOGY

HEMATOLOGY. 2024; 202:104455.  
DOI:10.1016/j.critrevonc.2024.104455.  
PMID:39067779. IF:5,500 (Q1/2D). Document type: Review.

- Agarwal N, Castellano D, Alonso T, Arijia J, Colomba E, Gravis G, Mourey L, Oudard S, Fléchon A, González M, Rey PM, Schweizer MT, Gallardo E, Johnston E, Balar A, Haddad N, Appiah AK, Nacerddine K, Piulats JM. A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1. CLINICAL CANCER RESEARCH. 2024; 30(11). DOI:10.1158/1078-0432.CCR-23-3436. PMID:38512117. IF:10,000 (Q1/1D). Document type: Article.
- Alserawan L, Mulet M, Anguera G, Riudavets M, Zamora C, Osuna R, Serra J, Joaquín AB, Sullivan I, Majem M, Vidal S. Kinetics of IFN?-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors. Cancers. 2024; 16(9):1759. DOI:10.3390/cancers16091759. PMID:38730712. IF:4,500 (Q1/3D). Document type: Article.
- Anguera G, Mulet M, Zamora C, Osuna R, Barba A, Sullivan I, Serra J, Cantó E, Vidal S, Majem M. Potential Role of Circulating PD-L1<SUP>+</SUP> <SUP>+</SUP> Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients. Biomedicines. 2024; 12(5):958. DOI:10.3390/biomedicines12050958. PMID:38790920. IF:3,900 (Q1/3D). Document type: Article.
- Aranha MR, Montal V, van den Brink H, Pegueroles J, Carmona M, Videla L, Blesa LM, Benejam B, Arranz J, Valldeneu S, Barroeta I, Fernández S, Ribas L, Alcolea D, González S, Bargalló N, Biessels GJ, Blesa R, Lleó A, Coutinho AM, Leite CC, Bejanin A, Fortea J. Cortical microinfarcts in adults with Down syndrome assessed with 3T-MRI. Alzheimers & Dementia. 2024; 20(6). DOI:10.1002/alz.13797. PMID:38644660. IF:13,000 (Q1/1D). Document type: Article.
- Arqueros C, Gallardo A, Vidal S, Osuna R, Tibau A, Bell OL, Cajal T, Lerma E, Lobato B, Salazar J, Barnadas A. Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative

- Breast Cancer Treated with Neoadjuvant Therapy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024; 25(5):2627. DOI:10.3390/ijms25052627. PMID:38473874. IF:4,900 (Q1/3D). Document type: Article.
- Barba A, López L, Ferré M, Majem M, Martínez S, Bell O, Arranz MJ, Salazar J, Sullivan I. *ERCC1* and *ERCC2* Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer. *Pharmaceutics*. 2024; 16(9):1121. DOI:10.3390/pharmaceutics16091121. PMID:39339159. IF:4,900 (Q1/2D). Document type: Article.
  - Bellmunt J, Maroto P, Bonfill T, Vázquez F, Pérez JL, Juanpere N, Hernández A, Hernández S, Rovira A, Juan OS, Rodríguez A. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study. *Clinical Genitourinary Cancer*. 2024; 22(5):102123. DOI:10.1016/j.clgc.2024.102123. PMID:38905731. IF:2,300 (Q2/5D). Document type: Article.
  - Borque A, Zapatero A, Manneh R, Alonso T, Couñago F, Domínguez M, López M, Rodríguez A, Sala N, Sanmamed N, Maroto P, Guard Invest Multidisciplinar Tumores Genitourinarios GRP. Recommendations on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Patient Selection. *Actas Urológicas Españolas*. 2024; 48(9). DOI:10.1016/j.acuro.2024.03.002. PMID:38740263. IF:1,200 (Q3/8D). Document type: Article.
  - Caballero M, Piedra A, Gallego O, López A, Castillo P, Navarrete P, Prat A, Grau JJ. Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. *Brazilian Journal of Otorhinolaryngology*. 2024; 90(6):101493. DOI:10.1016/j.bjorl.2024.101493. PMID:39205362. IF:1,700 (Q2/4D). Document type: Article.
  - Casanovas A, Estanyol B, Ciendones M, Padròs J, Cuartero J, Barnadas A, García B, González R, Sebio R, Masià J. Effectiveness of an Exercise and Educational-Based Prehabilitation Program in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy (PREOptimize) on Functional Outcomes: A Randomized Controlled Trial. *PHYSICAL THERAPY*. 2024; 104(12):pzae151. DOI:10.1093/ptj/pzae151. PMID:39423256. IF:3,500 (Q1/1D). Document type: Article.
  - Conde E, Hernández S, Carrillo JLR, Martínez R, Alonso M, Curto D, Jiménez B, Caminoa A, Benito A, Garrido P, Clave S, Arriola E, Esteban I, De Castro J, Sansano I, Felip E, Rojo F, Dómine M, Abdulkader I, García J, Teixido C, Reguart N, Compañ D, Insa A, Mancheño N, Palanca S, Juan O, Baixeras N, Nadal E, Cebollero M, Calles A, Martín P, Salas C, Provencio M, Aranda I, Massuti B, López L, Majem M, Paz L, López F. RET Fusion Testing in Patients With NSCLC: The RETING Study. *Jto Clinical And Research Reports*. 2024; 5(4):100653. DOI:10.1016/j.jtocr.2024.100653. PMID:38525319. Document type: Article.
  - Contreras D, Jiménez P, López CL, Montes AF, Muñoz A, Rivera FV, Alonso V, Alcaide J, Salvà F, Rúa MC, Guillot M, Carnicero AM, Mate RJ, García SC, Martínez EA, Astorga BG, Fernández AB, Villaroel PG, Manrique A, Sosa MM, Alonso B, Castiñeiras AC, López CC, Aparicio J, Carmona A. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?. *BRITISH JOURNAL OF CANCER*. 2024; 130(5). DOI:10.1038/s41416-023-02563-w. PMID:38191609. IF:6,400 (Q1/2D). Document type: Article.
  - Day E, Gavira J, Tapia JC, Anguera G, Maroto P. What About Variant Histologies in Bladder Cancer?. *European Urology Focus*. 2024; 10(2). DOI:10.1016/j.euf.2024.05.015. PMID:38849276. IF:4,800 (Q1/2D). Document type: Review.
  - Di AM, Schenker M, Medioni J, Mandziuk S, Majem M, Gravis G, Cornfeld M, Ranganathan S, Lou S, Csoszi T. A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203). *ESMO Open*. 2024; 9(3):102387. DOI:10.1016/j.

- esmoop.2024.102387. PMID:38401247. IF:7,100 (Q1/2D). Document type: Article.
- Escuin D, Bell O, García B, Clos M, Larrañaga I, López L, Mora J, Andrés M, Arqueros C, Barnadas A. Small Non-Coding RNAs and Their Role in Locoregional Metastasis and Outcomes in Early-Stage Breast Cancer Patients. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024; 25(7):3982. DOI:10.3390/ijms25073982. PMID:38612790. IF:4,900 (Q1/3D). Document type: Article.
  - Fernández A, Elez E, de la Haba J, Páez D, Méndez MJ, Felip E, Rodríguez A. Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology. Clinical & Translational Oncology. 2024; 26DOI:10.1007/s12094-023-03225-2. PMID:37316754. IF:2,800 (Q2/5D). Document type: Article.
  - Fernández CM, Sebio A, Rincón JO, Broto JM, Benlloch AM, Plaza DM, Pousa AL, Alegría IG, Giuppi M, Ballesteros EC, Bernabeu D, de Alava E, Morales CV. Clinical practice guidelines for the treatment of Ewing sarcoma (Spanish Sarcoma Research Group-GEIS). Clinical & Translational Oncology. 2024; DOI:10.1007/s12094-024-03602-5. PMID:39158802. IF:2,800 (Q2/5D). Document type: Review.
  - García P, Elez E, Soto J, Páez D, Fernández A, Graña B, Salud A, Yubero A, Gómez MA, Macías I, Quintero G, López C, Fernández T, Grávalos C, González E, Guix M, Paredes BG, Reina JJ, Mowbray JRR, Sastre J, Aranda E, Treatment Digestive Tumors TTD. Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial. ESMO Open. 2024; 9(12):103986. DOI:10.1016/j.esmoop.2024.103986. PMID:39608305. IF:7,100 (Q1/2D). Document type: Article.
  - García P, Jiménez P, Soto J, Baraibar I, Santos C, La Casta A, Ghanem I, Cortijo G, Méndez A, Pazo R, Vera R, Melián M, Alcaide J, Graña B, Páez D, Gallego I, Lobo M, Borregón M, Montes A, de Castro E, Carmona A, Aranda E, Spanish Cooperat Treatment Digest Tumors GRPTTD. Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study. ONCOLOGIST. 2024; DOI:10.1093/oncolo/oyae300. PMID:39550209. IF:4,800 (Q1/3D). Document type: Article.
  - Gately L, Mesía C, Sepúlveda JM, del Barco S, Pineda E, Gironés R, Fuster J, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Pérez P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martínez M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM). JOURNAL OF NEURO-ONCOLOGY. 2024; 168(2). DOI:10.1007/s11060-024-04668-5. PMID:38630385. IF:3,200 (Q2/3D). Document type: Article.
  - Gavira J, Tapia JC, Romano A, Anguera G, Aguado M, Piedra A, Bosma F, Sánchez S, Martín C, Algaba F, Arce Y, Cajal TRY, Maroto P. Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution. Clinical & Translational Oncology. 2024; 26(10). DOI:10.1007/s12094-024-03483-8. PMID:38722534. IF:2,800 (Q2/5D). Document type: Article.
  - Gray JE, Markovets A, Reungwetwattana T, Majem M, Nogami N, Peled N, Lee JS, Cho BC, Chewaskulyong B, John T, Han JY, Sebastián M, Todd A, Rukazenzov Y, Barrett C, Chmielecki J, Lee SM, Ramalingam SS, Hartmaier R. Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3. Journal of Thoracic Oncology. 2024; 19(11). DOI:10.1016/j.jtho.2024.07.008. PMID:39029876. IF:21,000 (Q1/1D). Document type: Article.
  - Gronchi A, Palmerini E, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Brunello A, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Pizzamiglio S, Verderio P, Fontana V, Donati DM, Palassini E, Sanfilippo R, Bianchi G, Bertuzzi A, Morosi C, Pasquali S, Stacchiotti

- S, Bagué S, Coindre JM, Miceli R, Dei AP, Casali PG. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(8). DOI:10.1200/JCO.23.00908. PMID:38232337. IF:42,100 (Q1/1D). Document type: Article.
- Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez MJ, Hong SH, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J, Choueiri TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Onkourologiya. 2024; 20(1). DOI:10.17650/1726-9776-2024-20-1-24-35. Document type: Article.
  - Krebs MG, Forster M, Majem M, Peguero J, Iams W, Clay T, Roxburgh P, Doger B, Bajaj P, Barba A, Perera S, Mueller C, Triebel F. Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study. Jto Clinical And Research Reports. 2024; 5(11):100725. DOI:10.1016/j.jtocrr.2024.100725. PMID:39403626. Document type: Article.
  - Lubinski J, Kotsopoulos J, Moller P, Pal T, Eisen A, Peck L, Karlan BY, Aeilts A, Eng C, Bordeleau L, Foulkes WD, Tung N, Couch FJ, Fruscio R, Cajal T, Singer CF, Neuhausen SL, Zakalik D, Cybulski C, Gronwald J, Huzarski T, Stempa K, Dungan J, Cullinane C, Olopade OI, Metcalfe K, Sun P, Narod SA, Hereditary Breast Canc C. MRI Surveillance and Breast Cancer Mortality in Women With *BRCA1* and *BRCA2* Sequence Variations. JAMA Oncology. 2024; DOI:10.1001/jamaoncol.2023.6944. PMID:38421676. IF:22,500 (Q1/1D). Document type: Article.
  - Mármol MCC, Aguado M, Cajal TRY, Gallardo A, Catasús L, González A, Méndez JE, Lasa A, Arumi M, Rubió OG, Serra JB, Hernández FM, von A, Kommos FKF, Espinosa I. Non-*C19MC*-altered embryonal tumor with multilayered rosettes in a young woman with DICER1 syndrome: case report and review of the literature. Pathologica. 2024; 116(3). DOI:10.32074/1591-951X-970. PMID:38979591. Document type: Review.
  - Martín B, Virgili AC, Riera P, Fumagalli C, Mirallas O, Pelegrín FJ, Sánchez S, Molina V, Szafranska J, Páez D. Histopathological, Clinical, And Molecular (HICAM) score for patients with colorectal liver metastases. BRITISH JOURNAL OF SURGERY. 2024; 111(3):znae016. DOI:10.1093/bjs/znae016. PMID:38488528. IF:8,600 (Q1/1D). Document type: Article.
  - Mateo FJP, Guasch AD, Pineda J, Manrique A, Cullell BM, López DP, Díaz JG, Cascón AP, Freiria XB. Capecitabine-Related Thrombotic Microangiopathy. Journal Of Gastrointestinal Cancer. 2024; 55(2). DOI:10.1007/s12029-023-00993-6. PMID:38175385. Document type: Article.
  - Mirallas O, Martín B, Navarro V, Vega KS, Recuero J, Gómez D, López D, de Torres CS, Andurell L, Pedrola A, Berché R, Palmas F, Ucha JM, Villacampa G, Rezqallah A, Sanz J, Bach R, Bueno S, Viaplana C, Molina G, Hernando A, Aguilar J, Roca M, Muñoz E, Martínez A, Alonso A, Eremiev S, Macarulla T, Oaknin A, Saura C, Élez E, Felip E, Peñuelas A, Burgos R, Pardo PG, Garralda E, Tabernero J, Serradell S, Servitja S, Páez D, Dienstmann R, Carles J. Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study. Lancet Regional Health-Europe. 2024; 46:101063. DOI:10.1016/j.lanepe.2024.101063. PMID:39529819. IF:13,600 (Q1/1D). Document type: Article.
  - Morcillo AO, Zsadyi SE, Arriola JE, Carmona M, Montal V, Pegueroles J, Aranha MR, Vaque L, Padilla C, Benejam B, Videla L, Barroeta I, Fernández S, Altuna M, Giménez S, González S, Bargallo N, Ribas L, Arranz J, Torres S, Iulita MF, Belbin O, Camacho V, Alcolea D, Lleó A, Fortea J, Bejanin A. Characterization of white matter hyperintensities in Down syndrome. Alzheimers & Dementia. 2024; 20(9). DOI:10.1002/alz.14146. PMID:39087352. IF:13,000 (Q1/1D). Document type: Article.

- Moreno JM, Feliubadaló L, Pineda M, Prada P, Ramos M, Del Valle J, Brunet J, Gel B, Currás M, Calsina B, Salazar ME, Rodríguez M, Roig B, Fernández S, Domínguez M, Ledo M, Sanz MI, Castillejo A, Dámaso E, Soto JL, de Miguel M, Calero B, Sánchez JM, Ramon T, Lasa A, Gisbert A, López A, Ruiz C, Potrony M, Álvarez M, Osorio A, Lorda I, Robledo M, Cascon A, Ruiz A, Spataro N, Hernan I, Borràs E, Moles A, Earl J, Cadiñanos J, Sánchez AB, Bigas A, Capellá G, Lazaro C, SpadaHC C. SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population. Database-The Journal of Biological Databases and Curation. 2024; 2024:baae055. DOI:10.1093/database/baae055. PMID:38965703. IF:3,400 (Q1/2D). Document type: Article.
- Motzer RJ, Porta C, Eto M, Powles T, Gruenwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani A, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez MJ, Kopyltsov E, Tjulandín S, Gordoá TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong SR, Bedke J, Schmidinger M, Rodríguez K, Burgents J, He CX, Okpara CE, Mckenzie J, Choueiri TK, CLEAR I. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(11). DOI:10.1200/JCO.23.01569. PMID:38227898. IF:42,100 (Q1/1D). Document type: Article.
- Ospina AV, Nadal SB, de la Cruz JLCC, Larriba JLG, Vidueira IM, Sureda BM, Nadal E, Tranco FH, Kindelan AA, Morillo E, Caro RB, Barrera JB, de Juan VC, Rubió JC, de Castro J, Ramos AC, Dols MC, Gómez M, Almanzar S, Campelo RG, Molla AI, Sarceda JRJ, Maestre UJ, Castro RL, Majem M, Martínez A, Tellez EM, Lorente DS, Provencio M. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP. Clinical & Translational Oncology. 2024; DOI:10.1007/s12094-024-03382-y. PMID:38530556. IF:2,800 (Q2/5D). Document type: Review.
- Palmerini E, Pousa AL, Grignani G, Redondo A, Hindi N, Provenzano S, Sebio A, Martín J, Valverde C, Trufero JM, Gutiérrez A, de Alava E, Gómez M, D'Ambrosio L, Collini P, Bazzocchi A, Moura DS, Ibrahim T, Stacchiotti S, Broto JM. Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial. CANCER. 2024; 131(1). DOI:10.1002/cncr.35628. PMID:39540661. IF:6,100 (Q1/2D). Document type: Article.
- Peressini M, García R, Massuti B, Martí C, Cobo M, Gutiérrez V, Dómine M, Fuentes J, Majem M, de Castro J, Córdoba JF, Diz MP, Isla D, Esteban E, Carcereny E, Vila L, Moreno A, Ros S, Moreno A, García FJ, Huidobro G, Aguado C, Cebey V, Valdivia J, Palmero R, Lianes P, López M, Vidal OJ, Provencio M, Arriola E, Baena J, Herrera M, Bote H, Molero M, Adradas V, Ponce S, Núñez A, Utero A, Hernández S, López F, Conde E, Paz L, Zugazagoitia J. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer. CLINICAL CANCER RESEARCH. 2024; 30(14). DOI:10.1158/1078-0432.CCR-24-0104. PMID:38630755. IF:10,000 (Q1/1D). Document type: Article.
- Piedra A, Martínez S, Hernández A, Morán T, Arriola E, Recuero J, Cobo M, Cordeiro P, Mosquera J, Fernández M, García R, Calles A, Álvarez R, Zapata M, Isla D, Callejo A, Iranzo P, Serra J, Barba A, Sullivan I, Felip E, Majem M. First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study. Frontiers in Oncology. 2024; 14:1510278. DOI:10.3389/fonc.2024.1510278. PMID:39741981. IF:3,500 (Q2/4D). Document type: Article.
- Provencio M, de Lope LR, Serna R, Nadal E, Tain PD, Massuti B, González JL, Insa A, Sánchez A, Casal J, García R, López SS, Rogado J, Martínez A, Bosch J, Bernabé R, Estévez SV, Ponce S, de Castro J, Sarto JC, Reguart N, Dómine M, Aguilar A, Majem M, Estival A, Cabia SP, Martín AL, González M, Cobo M, Camps C, Barneto I, Calvo V, Collazo A, Cruz A, Romero

- A. *BRAF* mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC. LUNG CANCER. 2024; 194:107865. DOI:10.1016/j.lungcan.2024.107865. PMID:38945004. IF:4,500 (Q1/2D). Document type: Article.
- Provencio M, Nadal E, Insa A, Campelo RG, Casal J, Dómine M, Massuti B, Majem M, Rodríguez D, Martínez A, de Castro J, de Antonio DG, Macia I, Figueroa S, Vago LF, Calvo V, Palmero R, Sierra B, Martínez C, Molina M, Serna R, Romero A, Cruz A. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. LANCET ONCOLOGY. 2024; 25(11). DOI:10.1016/S1470-2045(24)00498-4. PMID:39419061. IF:41,600 (Q1/1D). Document type: Article.
  - Puente J, Pinto A, Méndez MJ, del Muro XG, Maroto P, Vázquez S, Luque R, Anido U, Strunz T, Upadhyay A, Montes J, Núñez AO, Portela JG, Castellano D. Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain. Clinical & Translational Oncology. 2024; DOI:10.1007/s12094-024-03734-8. PMID:39365365. IF:2,800 (Q2/5D). Document type: Article.
  - Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Prelaj A, López R, Bosch J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Nana FA, Ponce S, Albarrán V, Dal A, Spotti M, Mielgo X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier JB, Audigier C, Scheffler M, Nadal E, Lopes G, Signorelli D, García R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Mezquita L, Planchard D. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 2024; 25(3). DOI:10.1016/j.clcc.2023.11.007. PMID:38105153. IF:3,300 (Q2/4D). Document type: Article.
  - Rodríguez A, Valderrama BP, Castellano D, Pinto A, Mellado B, Puente J, Climent MA, Domenech M, Vázquez F, Pérez JL, Bonfill T, Morales R, González E, García X, Maroto P, Navarro N, Juanpere N, Juan O, Bellmunt J. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study. ESMO Open. 2024; 9(9):103690. DOI:10.1016/j.esmoop.2024.103690. PMID:39214051. IF:7,100 (Q1/2D). Document type: Article.
  - Rofes P, Dueñas N, del Valle J, Navarro M, Balmaña J, Ramón y Cajal T, Tuset N, Castillo C, González S, Brunet J, Capellá G, Lázaro C, Pineda M. Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation. Cancer Medicine. 2024; 13(7):e7041. DOI:10.1002/cam4.7041. PMID:38558366. IF:2,900 (Q2/5D). Document type: Article.
  - Rueda AG, Taus A, Álvarez RA, Bernabé R, Chara L, López M, Vilà L, González M, Aldagalán A, Herrera BE, Castro RL, Cabellos RA, Doménech M, Falagan S, Vega AM, Aguado C, Barba A, Ureña MTD, Isla D, Hernández LB, Pérez JLF, Juan O, Massuti B, Mielgo X, Ortega AL, Catot S, Dómine M, Escoín C, Navalón FG, Gil I, Muñoz S, Rodríguez D, Roldán RMV, Curbera GA, León L, Padilla A, Lario AP, Sánchez JM, Garrido P, Spanish Lung Canc GRP. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Clinical & Translational Oncology. 2024; 26(9). DOI:10.1007/s12094-024-03404-9. PMID:38512450. IF:2,800 (Q2/5D). Document type: Article.
  - Salazar J, Arranz MJ, Martín J, Bautista F, Martínez J, Martínez J, Vidal Y, Echebarria A, Díaz R, Valverde C, Luna P, Vaz MA, Blay P, Álvarez R, Sebio A. Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol. Pharmaceutics. 2024; 16(12):1585. DOI:10.3390/pharmaceutics16121585. PMID:39771563. IF:4,900 (Q1/2D). Document type: Article.
  - Salazar J, García E, Fernández A, Esteve M, Gisbert JP, Busquets D, Lucendo A, Márquez L, Guardiola J, Martín MD, Iglesias E, Monfort D,

- Villoria A, Cañete F, Bell O, Ricart E, Zabana Y, Chaparro M, Domènech E, Gordillo J, ENEIDA G. Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2024; 90(5). DOI:10.1111/bcp.16017. PMID:38369687. IF:3,100 (Q2/4D). Document type: Article.
- Salazar J, Riera P, Gordillo J, Altès A, Martínez M, Serès M, Llaó J, Giordano A, García E. Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn's disease patients. PHARMACOGENOMICS JOURNAL. 2024; 24(4):20. DOI:10.1038/s41397-024-00341-2. PMID:38906864. IF:2,900 (Q2/5D). Document type: Article.
  - Santero M, Meade AG, Selva A, Savall O, Bracchiglione J, Macías I, Leache L, Cerdà P, Cosp XB, Appropriateness Systemic Oncological Treatment Adv Canc ASTAC R. Utilising systematic reviews to assess potential overtreatment and claim for better evidence-based research: an analysis of anticancer drugs versus supportive care in advanced esophageal cancer. Systematic Reviews. 2024; 13(1):186. DOI:10.1186/s13643-024-02594-1. PMID:39026378. IF:6,300 (Q1/1D). Document type: Article.
  - Schreurs M, Cajal TRY, Adank MA, Collee JM, Hollestelle A, van J, Schmidt MK, Hooning MJ. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families. BREAST. 2024; 73:103611. DOI:10.1016/j.breast.2023.103611. PMID:38039887. IF:5,700 (Q1/1D). Document type: Article.
  - Shachar SS, Korzets Y, Shepshelovich D, Zlothover N, Amir E, Tibau A, Goldvaser H. Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review. CANCER TREATMENT REVIEWS. 2024; 122:102666. DOI:10.1016/j.ctrv.2023.102666. PMID:38064877. IF:9,600 (Q1/1D). Document type: Review.
  - Tapia JC, Bosma F, Gavira J, Sánchez S, Molina MA, Sanz J, Martín C, Anguera G, Maroto P. Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021. Clinical Genitourinary Cancer. 2024; 22(3):102047. DOI:10.1016/j.clgc.2024.01.019. PMID:38430859. IF:2,300 (Q2/5D). Document type: Article.
  - Tapia JC, Gavira J, Anguera G, Sánchez S, Romano A, Bosma F, Molina A, Sanz J, Martín C, Algaba F, Maroto P. Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk-adapted strategy: a Spanish single-centre retrospective analysis. Clinical & Translational Oncology. 2024; 26(7). DOI:10.1007/s12094-024-03393-9. PMID:38421563. IF:2,800 (Q2/5D). Document type: Article.
  - Tibau A, Hwang TJ, Avorn J, Kesselheim AS. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study. BMJ-British Medical Journal. 2024; 386:e079126. DOI:10.1136/bmj-2023-079126. PMID:39164034. IF:93,600 (Q1/1D). Document type: Article.
  - Tibau A, Hwang TJ, Molto C, Avorn J, Kesselheim AS. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies. JAMA Oncology. 2024; 10(5). DOI:10.1001/jamaoncol.2024.0194. PMID:38573645. IF:22,500 (Q1/1D). Document type: Article.
  - Torres S, Llop A, Gutiérrez S, Romey M, Teulé A, Llor G, Herrero A, Sánchez P, Vallmajó A, González S, Chirivella I, Cano JM, Graña B, Simónetti S, de Corcuera ID, Cajal TRY, Sanz J, Serrano S, Otero A, Churruca C, Sánchez AB, Servitja S, Guillén C, Brunet J, Denkert C, Serra V, Balmaña J. Prevalence

- of Homologous Recombination Deficiency Among Patients With Germline *RAD51C*/D Breast or Ovarian Cancer. JAMA Network Open. 2024; 7(4):e247811. DOI:10.1001/jamanetworkopen.2024.7811. PMID:38648056. IF:10,500 (Q1/1D). Document type: Article.
- Vidal N, Climent MA, Pérez S, Méndez MJ, Anguera G, Salas IM, Gallardo E, Cuéllar MA, Molina J, Martín A, Rodríguez A, Casado EA, González M, Domènech M, Kareaga MM, Calvo OF, Guzmán JCV, Estévez SV, González A, Puente J. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study. Clinical & Translational Oncology. 2024; DOI:10.1007/s12094-024-03744-6. PMID:39369361. IF:2,800 (Q2/5D). Document type: Article.
  - Viñolas N, Mezquita L, Corral J, Cobo M, Gil F, Paz L, Remon J, Rodríguez M, Ruano A, Conde E, Majem M, Garrido P, Felip E, Isla D, de Castro J. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium. Clinical & Translational Oncology. 2024; 26(2). DOI:10.1007/s12094-023-03262-x. PMID:37490262. IF:2,800 (Q2/5D). Document type: Article.
  - Virgili AC, Salazar J, Gallardo A, López A, Terés R, Bagué S, Orellana R, Fumagalli C, Mangues R, Alba L, Unzueta U, Casanova I, Sebio A. CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas. Diagnostics. 2024; 14(11):1195. DOI:10.3390/diagnostics14111195. PMID:38893721. IF:3,000 (Q1/2D). Document type: Article.
  - Waterhouse DM, Rothschild S, Dooms C, Mennezier B, Bozorgmehr F, Majem M, Heuvel MHV, Linardou H, Cho BC, Roberts R, Tanaka K, Blais N, Schvartsman G, Hansen KH, Chmielewska I, Forster MD, Giannopoulou C, Stollenwerk B, Obiozor CC, Wang Y, Novello S. Patient-reported outcomes in CodeBreak 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with *KRAS* G12C mutation. LUNG CANCER. 2024; 196:107921. DOI:10.1016/j.lungcan.2024.107921. PMID:39303400. IF:4,500 (Q1/2D). Document type: Article.